A study reveals that the APOE3-R136S mutation delays Alzheimer’s disease by inhibiting the cGAS-STING immune pathway. This mutation suppresses inflammation in brain-resident immune cells, offering ...

The scientists showed that the mutation inhibits the cGAS-STING pathway, an innate immune signaling cascade that is abnormally activated in Alzheimer’s and other neurodegenerative diseases.

The planned phase 1b/2 clinical trial plans to evaluate LP-184 in advanced NSCLC patients with KEAP1 and/or STK11 mutations and low expression of PD-L1 in combination with the immune checkpoint ...

Using genetic analysis, Duh and colleagues identified a mutation in the KEAP1 gene in horses, donkeys, and zebras. This mutation introduced a stop codon, or a sequence in the genetic code that is the ...

They found that mutations in the STK11 and KEAP1 genes were linked to a less favorable tumor environment, often referred to as a "cold" microenvironment.

The TRITON study stems from an exploratory analysis of the POSEIDON trial, which looked at how the presence of STK11 and/or KEAP1 and/or KRAS mutations may affect treatment for nonsquasmous NSCLC ...

Davidson's previous research found that tumors arising from a KEAP1 mutation are extremely sensitive to deprivation of glutamine, an amino acid cells need for several essential processes.

We summarize drug resistance pathways such as the KEAP1/Nrf2 pathway MAPK pathway, and NF-κB pathway. Also, we analyze the limitations and conditions for the application of genome-wide CRISPR/Cas9 ...